Volume 69, Issue 4, Pages (October 2018)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Volume 61, Issue 2, Pages (August 2014)
Volume 63, Issue 1, Pages (July 2015)
Volume 65, Issue 3, Pages (September 2016)
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 46, Issue 3, Pages (March 2007)
Volume 59, Issue 1, Pages (July 2013)
The impact of hepatitis E in the liver transplant setting
Inflammasomes in liver diseases
Volume 61, Issue 4, Pages (October 2014)
Volume 50, Issue 4, Pages (April 2009)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis  Wichit Srikureja,
Volume 68, Issue 5, Pages (May 2018)
Volume 42, Issue 6, Pages (June 2005)
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
The impact of hepatitis E in the liver transplant setting
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 147, Issue 1, Pages (July 2014)
NS5A inhibitors in the treatment of hepatitis C
Immigration and viral hepatitis
Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis  Astrid Marot, Jean Henrion, Jean-François.
Hepatitis B and C virus-related carcinogenesis
Suna Yapali, Nizar Talaat, Anna S. Lok 
Volume 69, Issue 1, Pages (July 2018)
Living donor liver transplantation: is the hype over?
Volume 69, Issue 2, Pages (August 2018)
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
Volume 65, Issue 4, Pages (October 2016)
European Association for the Study of the Liver  Journal of Hepatology 
Volume 68, Issue 1, Pages (January 2018)
Hepatitis C core protein – The “core” of immune deception?
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Nghia H. Nguyen, Vincent Nguyen, Huy N. Trinh, Brian Lin, Mindie H
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Genomic risk of hepatitis C-related hepatocellular carcinoma
Autophagy in the liver Journal of Hepatology
Volume 65, Issue 6, Pages (December 2016)
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Volume 61, Issue 1, Pages S45-S57 (November 2014)
Volume 44, Issue 2, Pages (February 2006)
Hepatitis B and C virus-related carcinogenesis
Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis  Dr Shevanthi Nayagam,
Volume 50, Issue 4, Pages (April 2009)
Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer.
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Volume 67, Issue 5, Pages (November 2017)
Volume 56, Issue 6, Pages (June 2012)
Volume 50, Issue 3, Pages (March 2009)
Immigration and viral hepatitis
HCV targeting of patients with cirrhosis
Volume 64, Issue 6, Pages (June 2016)
Volume 63, Issue 1, Pages (July 2015)
Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection  Isabelle Chemin,
Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences  Zobair M. Younossi, Aybike Birerdinc,
Chronic hepatitis B in children and adolescents
Volume 66, Issue 3, Pages (March 2017)
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
Scott K. Fung, Anna S.F. Lok  Clinical Gastroenterology and Hepatology 
Outcomes in liver transplantation: Does sex matter?
Reversion of disease manifestations after HCV eradication
Friedrich Foerster, Peter Robert Galle  JHEP Reports 
Presentation transcript:

Volume 69, Issue 4, Pages 776-784 (October 2018) Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa  Yusuke Shimakawa, Ramou Njie, Gibril Ndow, Muriel Vray, Papa Saliou Mbaye, Philippe Bonnard, Roger Sombié, Jean Nana, Vincent Leroy, Julie Bottero, Patrick Ingiliz, Gerrit Post, Bakary Sanneh, Ignatius Baldeh, Penda Suso, Amie Ceesay, Adam Jeng, Harr Freeya Njai, Shevanthi Nayagam, Umberto D'Alessandro, Isabelle Chemin, Maimuna Mendy, Mark Thursz, Maud Lemoine  Journal of Hepatology  Volume 69, Issue 4, Pages 776-784 (October 2018) DOI: 10.1016/j.jhep.2018.05.024 Copyright © 2018 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2018 69, 776-784DOI: (10. 1016/j. jhep. 2018. 05 Copyright © 2018 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Flow diagram of study participants. HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D virus; HIV, human immunodeficiency virus; LSM, liver stiffness measurement. Journal of Hepatology 2018 69, 776-784DOI: (10.1016/j.jhep.2018.05.024) Copyright © 2018 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Proportion of patients eligible for treatment according to each of the international guidelines, by the total point (0–4) of TREAT-B. The number of patients with the TREAT-B score of 0, 1, 2, 3, and 4 was 214, 457, 93, 33, and 7 in the derivation set, and 32, 185, 68, 36, and 6 in the validation set, respectively. AASLD, American Association for the Study of Liver Diseases; APASL, Asian Pacific Association for the Study of the Liver; EASL, European Association for the Study of the Liver; TREAT-B, treatment eligibility in Africa for the hepatitis B virus. Journal of Hepatology 2018 69, 776-784DOI: (10.1016/j.jhep.2018.05.024) Copyright © 2018 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Calibration plot for TREAT-B for indicating treatment eligibility based on the EASL guidelines. EASL, European Association for the Study of the Liver; TREAT-B, treatment eligibility in Africa for the hepatitis B virus. Journal of Hepatology 2018 69, 776-784DOI: (10.1016/j.jhep.2018.05.024) Copyright © 2018 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Receiver operating characteristic curves for TREAT-B, WHO, and REACH-B to indicate EASL treatment eligibility. EASL, European Association for the Study of the Liver; REACH-B, Risk estimation for hepatocellular carcinoma in chronic hepatitis B; TREAT-B, treatment eligibility in Africa for the hepatitis B virus; WHO, World Health Organization. (This figure appears in colour on the web.) Journal of Hepatology 2018 69, 776-784DOI: (10.1016/j.jhep.2018.05.024) Copyright © 2018 European Association for the Study of the Liver Terms and Conditions